Keyphrases
Recombinant Protein
100%
Filovirus
100%
Marburg Virus
100%
Ebola Virus
100%
Filovirus Vaccine
100%
Cynomolgus Macaque
100%
Sudan Virus
100%
Vaccine Candidate
40%
Monovalent Cations
40%
Recombinant Vaccine
40%
Virus
20%
Immune Response
20%
Fatality
20%
Guinea pig
20%
Adverse Reactions
20%
Vaccine Antigen
20%
Recombinant
20%
Sudan
20%
Glycoprotein
20%
Preclinical Testing
20%
Therapeutic Targeting
20%
Human Population
20%
Nonhuman Primate
20%
Experimental Therapeutics
20%
Safety Concerns
20%
Serum IgE
20%
Mandatory Vaccines
20%
Antigen-specific
20%
Vaccine Platform
20%
Lethal Dose
20%
Endemic Region
20%
Primates
20%
Multivalent Vaccine
20%
Marburg
20%
Ebola
20%
Challenge Model
20%
IgG Titer
20%
West African
20%
Epidemic Potential
20%
Virus Diseases
20%
Drosophila S2 Cells
20%
Cynomolgus
20%
Full Protection
20%
Clinical Chemistry
20%
Two-dose
20%
Democratic Republic of Congo
20%
Emergency Department Use
20%
Bivalent Vaccine
20%
Challenge Study
20%
Delayed Onset
20%
Ebola Virus Disease
20%
Reaction Chemistry
20%
CoVaccine HT™
20%
Pharmacology, Toxicology and Pharmaceutical Science
Recombinant Protein
100%
Marburg Virus
100%
Filovirus
100%
Ebola Virus
100%
Macaca fascicularis
100%
Infection
50%
Subunit Vaccine
33%
Adverse Event
16%
Fatality
16%
Guinea Pig
16%
Glycoprotein
16%
Virus Infection
16%
Experimental Therapeutic
16%
Ebola Virus Disease
16%
Lethal Dose
16%
Immunology and Microbiology
Filovirus
100%
Marburgvirus
100%
Macaca fascicularis
100%
Infection
50%
Subunit Vaccine
33%
Virus
33%
Immune Response
16%
Antigen Specificity
16%
Guinea Pig
16%
Glycoprotein
16%
Titer
16%
Ebola Virus
16%
Lethal Dose
16%